

AD\_\_\_\_\_

Award Number: W81XWH-07-1-0390

**TITLE:** Targeting Signal Transducers and Activators of Transcription-3 (Stat3) As a Novel Strategy In Sensitizing Breast Cancer To Egfr-Targeted Therapy

**PRINCIPAL INVESTIGATOR:** Hui-Wen Lo, Ph.D.

**CONTRACTING ORGANIZATION:** Duke University  
Durham, NC 27708

**REPORT DATE:** June 2008

**TYPE OF REPORT:** Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE 30-06-2008	2. REPORT TYPE Annual	3. DATES COVERED 1 JUN 2007 - 31 MAY 2008		
4. TITLE AND SUBTITLE  Targeting Signal Transducers And Activators of Transcription-3 (Stat3) As A Novel Strategy In Sensitizing Breast Cancer To Egfr-Targeted Therapy		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER W81XWH-07-1-0390		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Hui-Wen Lo, Ph.D.  Email: huiwen.lo@duke.edu		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Duke University Durham, NC 27708		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT  We have performed proposed studies to test the hypothesis that deregulated EGFR and STAT3 pathways synergistically contribute to the malignant biology of breast cancer and that combined uses of anti-EGFR and anti-STAT3 treatments result in significantly increased breast cancer cell death compared to single agent treatments. Analysis of a panel of human breast cancer cell lines and primary breast carcinoma specimens revealed that EGFR and constitutively activated STAT3 (p-STAT3) are frequent and concurrent. EGFR and STAT3 cooperate to induce epithelial mesenchymal transition by activating expression of TWIST, an E-cadherin repressor. In breast cancer cells with high levels of EGFR and p-STAT3, forced expression of dominant-negative STAT3 significantly suppresses cell proliferation. Importantly, dominant-negative STAT3 sensitizes breast cancer cells with high EGFR/p-STAT3 to anti-EGFR agent, Iressa. In contrast, transfection of constitutively active STAT3 into these cells does not increase cell proliferation nor induces resistance to Iressa, suggesting the endogenous p-STAT3 is sufficient in facilitating cell survival. Consistently, breast cancer cells with no or low EGFR expression do not respond to Iressa treatments. Together, the findings to date point to significant in vivo and in vitro interactions between EGFR and STAT3 oncoproteins in breast cancer as well as a role of STAT3 constitutive activation may play in the resistance of these tumors to anti-EGFR therapy.				
15. SUBJECT TERMS EGFR, STAT3, drug resistance, signal cross-talks				
16. SECURITY CLASSIFICATION OF:  a. REPORT U		17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 23	19a. NAME OF RESPONSIBLE PERSON USAMRMC
b. ABSTRACT U				19b. TELEPHONE NUMBER (include area code)
c. THIS PAGE U				

## Table of Contents


	<u>Page</u>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>6</b>
<b>Reportable Outcomes.....</b>	<b>6</b>
<b>Conclusion.....</b>	<b>6</b>
<b>References.....</b>	<b>7</b>
<b>Appendices.....</b>	<b>7</b>

## INTRODUCTION

The proposal is built on the following observations from our studies and others. **(i)** Single use of EGFR-targeted therapy, gefitinib/Iressa (an EGFR tyrosine kinase inhibitor) and cetuximab (an EGFR blocking antibody), demonstrated a moderate therapeutic effect in breast cancer patients. **(ii)** Both EGFR and STAT3 are oncoproteins and frequently over-expressed and/or constitutively activated in breast cancer (2). We observed co-overexpression of both EGFR and p-STAT3 in 60% of EGFR-positive breast carcinomas (3). **(iii)** STAT3 is constitutively activated in 50% of the breast cancer and can be activated by EGFR and other growth factor- and cytokine pathways (4, 5). **(iv)** Iressa-treated breast cancer cells and clinical specimens displayed insufficient suppression of STAT3 activity despite with complete EGFR inhibition (3, 6). **(v)** Although EGFR and STAT3 can mediate different downstream targets, our recent study indicated that they cross-talk at multiple levels (3). **(vi)** We showed that combined use of anti-EGFR and anti-STAT agent resulted in synergistic cell death in MDA-MB-468 human breast carcinoma cells who express high levels of EGFR and p-STAT3 (3). Based on these rationales, **we hypothesize that deregulated EGFR and STAT3 pathways synergistically contribute to the malignant biology of breast cancer and that combined uses of anti-EGFR and anti-STAT3 treatments result in significantly increased breast cancer cell death compared to single agent treatments.** The outcome from this proposal is likely to help us achieve the long-term goal of the study, which is to better understand the malignant biology of breast cancer including those with de-regulated EGFR pathway and to provide rationales for more effective therapies for women with breast cancer. **AIM 1:** To determine whether increased STAT3 activity confers resistance to anti-EGFR therapies in EGFR-expressing breast cancer cells. **AIM 2:** To investigate whether suppression of STAT3 expression/activity sensitizes EGFR/p-STAT3-expressing breast cancer cells to anti-EGFR therapies. **AIM 3:** To determine the therapeutic effects of combined use of anti-EGFR and anti-STAT3 treatments in a mammary tumor-bearing animal model.


## BODY

**Significant co-expression of EGFR and constitutively activated STAT3 in approximately 40% of a cohort of primary breast carcinomas (Task 1a).** We observed a positive correlation between EGFR and STAT3 constitutive activation in a cohort of 132 primary breast carcinomas by regression analysis (3A) and Chi-square analysis (3B) (7). Intriguingly, we found 38.6% (51/132) of the primary breast tumors to over-express both EGFR and constitutively activated STAT3. Representative tumors are shown in panel 3B.



**Figure 1 Significant co-overexpression of EGFR and p-STAT3 in primary breast carcinomas.** Regression (A) and Chi-square (B) analyses were performed in a cohort of human breast carcinomas. In Chi-square analyses, tumors with  $\leq 35\%$  cells staining positive for EGFR were considered with the low levels whereas those with  $> 35\%$ , high levels according to previously established classification system (1). As for p-STAT3, tumors with  $\geq 20\%$  cells with positive staining were regarded as constitutively activated, using a well-established system. **C:** Representative tumors: Left: High EGFR/p-STAT3, Right: Low EGFR/p-STAT3.

**Significant co-expression of EGFR and constitutively activated STAT3 in cultured breast cancer cells (Task 1a-c).** In light of the *in vivo* observation showing that EGFR frequently co-expresses with p-STAT3 in primary carcinomas, we further examine whether this correlation exists in culture human breast cancer cells. As shown in Fig. 2A, seven out of eight cell lines that we examined express constitutively activated STAT3. These seven cell lines also express medium to high levels of EGFR, consistent with the role of EGFR as a STAT3-phosphorylating kinase. We also determined their response to Iressa (Fig. 2B) and found that most lines are resistant to Iressa treatments despite EGFR expression and that MCF-7 cells are most resistance likely due to its low dependency of EGFR. Moreover, we transiently transfected constitutively activated STAT3 (STAT3CA) to MDA-MB-468, Hs578T, BT-20 and SK-BR-3 cells and determine Iressa sensitivity, but did not find STAT3CA to increase Iressa resistance. We speculate that this is due to the high endogenous p-STAT3 in these lines which is sufficient to constitute Iressa resistance without additional p-STAT3. But we will commit future effort to confirm this observation using stable transfection and by identifying cell lines with low endogenous p-STAT3 but high EGFR and high Iressa sensitivity.




**Figure 2 Significant co-expression of EGFR and constitutively activated STAT3 in cultured breast cancer cells.**

**A:** A panel of human breast cancer cell lines was analyzed for EGFR and STAT3/p-STAT3 expressing using western blotting.

**B:** Cancer cells were treated with various concentrations of Iressa for 48 hrs and survival rates determined.

**Dominant-negative STAT3 leads to growth suppression and sensitization to anti-EGFR treatments in two human breast cancer cell lines (Task 2a).** In light of the high level of STAT3 constitutive activation observed in human breast cancer, we next examine whether suppressing STAT3 activity using dominant-negative STAT3 (STAT3-DN) inhibits their growth and/or sensitizes them to anti-EGFR treatments. As shown in Fig. 3A, forced expression of STAT3-DN significantly killed Hs578T and MDA-MB-468 cells who express high levels of p-STAT3. Importantly, STAT3-DN also sensitizes both cell lines to Iressa treatments (Fig. 3B). As indicated in Fig. 3C, STAT3-DN transfection was effective.



**Functional interactions between EGFR and STAT3 in promoting breast cancer progression (7).** Aberrant EGFR signaling is a major cause of tumor progression and metastasis, the underlying mechanisms, however, are not well understood. In particular, it remains elusive whether deregulated EGFR pathway is involved in epithelial-mesenchymal transition (EMT), an early event that occurs during metastasis of cancers of an epithelial origin. Here, we show that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology. EGF reduced E-cadherin expression and increased that of mesenchymal proteins. In search of a downstream mediator that may account for EGF-induced EMT, we focused on transcription repressors of E-cadherin, TWIST, SLUG and Snail, and found that cancer cells express high levels of TWIST and that EGF enhances its expression. EGF significantly increases TWIST transcripts and protein in EGFR-expressing lines. Forced expression of EGFR re-activates TWIST expression in EGFR-null cells. TWIST expression is suppressed by EGFR and Jak/STAT3 inhibitors, but not significantly by those targeting PI3K and MEK. Furthermore, constitutively active STAT3 significantly activates the TWIST promoter, whereas the JAK/STAT3 inhibitor and dominant-negative STAT3 suppressed TWIST promoter. Deletion/mutation studies further show that a 26 bp promoter region contains putative STAT3 elements required for the EGF-responsiveness of the TWIST promoter. Chromatin immunoprecipitation assays further demonstrate that EGF induces binding of nuclear STAT3 to the TWIST promoter. Immunohistochemical analysis of 130 primary breast carcinomas indicates positive correlations between non-nuclear EGFR and TWIST and between p-STAT3 and TWIST. Together, we report here that EGF/EGFR signaling pathways induces cancer cell EMT via STAT3-mediated TWIST gene expression (manuscript reprint provided).

## KEY RESEARCH ACCOMPLISHMENTS

- Significant co-expression of EGFR and constitutively activated STAT3 in primary breast carcinomas and cultured breast cancer cells.
- Functional interactions between EGFR and STAT3 in promoting breast cancer progression.
- Dominant-negative STAT3 leads to growth suppression and sensitization to anti-EGFR treatments in two human breast cancer cell lines.

## REPORTABLE OUTCOMES

### A: Manuscript

Lo, H.-W., Hsu, S.-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N. and Hung, M.-C. Epidermal Growth Factor Receptor Cooperates with Signal transducer and activator of transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. *Cancer Research* 67:9066-76, 2007 (7).

### B: Funding applied based on work supported by this award

Research Scholar Grant	Lo (PI)	1/1/2009-12/31/2012
American Cancer Society		
De-regulated EGFR and STAT3 pathways in breast cancer EMT and intravasation		
Synergistic Idea Award	Lo (PI)	4/1/2009-3/31/2011
Breast Cancer Research Program		
Department of Defense		
RNA Aptamers as a Novel Targeted Therapy for Breast Cancer with Aberrant EGFR and STAT3 Pathways		

## CONCLUSION

Our research effort in the past award year has resulted in several interesting findings and a publication that support the study hypothesis: deregulated EGFR and STAT3 pathways synergistically contribute to the malignant biology of breast cancer and that combined uses of anti-EGFR and anti-STAT3 treatments result in significantly increased breast cancer cell death compared to single agent treatments. First, we found significant co-expression of EGFR and constitutively activated STAT3 in approximately 40% of a cohort of primary breast carcinomas and in the majority of cultured human breast cancer cells. Second, consistent with the co-expression, suppressing STAT3 activity by STAT3-DN leads to growth suppression and sensitization to anti-EGFR treatments in two human breast cancer cell lines. Finally, we found that functional interactions between EGFR and STAT3 promote breast cancer progression via activating TWIST gene expression. Together, these promising results prompt us to further explore the role of STAT3 activation in the resistance of human breast cancer cells to anti-EGFR therapy in the next award year.

## REFERENCE

1. Lo, H. W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S. F., and Hung, M. C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. *Cancer Res*, 2005,65: 338-348.
2. Lo, H. W., Hsu, S. C., and Hung, M. C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. *Breast Cancer Res Treat*, 2005: 1-8.
3. Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., and Hung, M.-C. Nuclear Interaction of EGFR and STAT3 in the Activation of iNOS/NO Pathway. *Cancer Cell*, 2005,7: 575-589.
4. Garcia, R., Yu, C. L., Hudnall, A., Catlett, R., Nelson, K. L., Smithgall, T., Fujita, D. J., Ethier, S. P., and Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. *Cell Growth Differ*, 1997,8: 1267-1276.
5. Yu, H. and Jove, R. The STATs of cancer--new molecular targets come of age. *Nat Rev Cancer*, 2004,4: 97-105.
6. Albanell, J., Rojo, F., and Baselga, J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. *Semin Oncol*, 2001,28: 56-66.
7. Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N., and Hung, M. C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. *Cancer Res*, 2007,67: 9066-9076.

## APPENDICES

### A: Manuscript Reprint

**Lo, H.-W., Hsu, S-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N. and Hung, M.-C. Epidermal Growth Factor Receptor Cooperates with Signal transducer and activator of transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. *Cancer Research* 67:9066-76, 2007.**

### B: CV

# Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of *TWIST* Gene Expression

Hui-Wen Lo,<sup>1,2</sup> Sheng-Chieh Hsu,<sup>2</sup> Weiya Xia,<sup>2</sup> Xinyu Cao,<sup>1</sup> Jin-Yuan Shih,<sup>2,6</sup> Yongkun Wei,<sup>2</sup> James L. Abbruzzese,<sup>3</sup> Gabriel N. Hortobagyi,<sup>4</sup> and Mien-Chie Hung<sup>2,5,7</sup>

<sup>1</sup>Department of Surgery, The Comprehensive Cancer Center, Duke University, Durham, North Carolina; Departments of <sup>2</sup>Molecular and Cellular Oncology, <sup>3</sup>Gastrointestinal Medical Oncology, <sup>4</sup>Breast Medical Oncology and <sup>5</sup>Graduate School of Biomedical Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; <sup>6</sup>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; and <sup>7</sup>Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan

## Abstract

Aberrant epidermal growth factor receptor (EGFR) signaling is a major cause of tumor progression and metastasis; the underlying mechanisms, however, are not well understood. In particular, it remains elusive whether deregulated EGFR pathway is involved in epithelial-mesenchymal transition (EMT), an early event that occurs during metastasis of cancers of an epithelial origin. Here, we show that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology. EGF reduced E-cadherin expression and increased that of mesenchymal proteins. In search of a downstream mediator that may account for EGF-induced EMT, we focused on transcription repressors of E-cadherin, TWIST, SLUG, and Snail and found that cancer cells express high levels of TWIST and that EGF enhances its expression. EGF significantly increases TWIST transcripts and protein in EGFR-expressing lines. Forced expression of EGFR reactivates *TWIST* expression in EGFR-null cells. *TWIST* expression is suppressed by EGFR and Janus-activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) inhibitors, but not significantly by those targeting phosphoinositide-3 kinase and MEK/ERK. Furthermore, constitutively active STAT3 significantly activates the TWIST promoter, whereas the JAK/STAT3 inhibitor and dominant-negative STAT3 suppressed *TWIST* promoter. Deletion/mutation studies further show that a 26-bp promoter region contains putative STAT3 elements required for the EGF-responsiveness of the TWIST promoter. Chromatin immunoprecipitation assays further show that EGF induces binding of nuclear STAT3 to the *TWIST* promoter. Immunohistochemical analysis of 130 primary breast carcinomas indicates positive correlations between non-nuclear EGFR and TWIST and between phosphorylated STAT3 and TWIST. Together, we report here that EGF/EGFR signaling pathways induce cancer cell EMT via STAT3-mediated *TWIST* gene expression. [Cancer Res 2007;67(19):9066–76]

## Introduction

Accumulating evidences suggest a role of epidermal growth factor receptor (EGFR) in tumor metastasis (1–5). It has been reported that EGFR activates its downstream modules protein kinase C- $\delta$ , extracellular signal-regulated kinase (ERK), and phospholipase C- $\gamma$  and facilitates migration of EGFR-overexpressing cancer cells (6, 7). It has also been shown that EGFR increases production of matrix metalloproteinase-9, possibly via phosphoinositide-3 kinase (PI3K), leading to cell migration (8, 9). However, the involvement of EGFR in epithelial-mesenchymal transition (EMT; an early step during tumor metastasis) remains elusive. Nevertheless, chronic EGF treatment has been shown to lead to down-regulation of E-cadherin expression and loss of cell-cell adherence junction (10). Down-regulation of E-cadherin is considered as a critical step and an indicator for EMT, and the down-regulation of which can be achieved by transcriptional suppression mediated by transcription factors TWIST, SLUG, and Snail (11–14).

TWIST is a basic helix-loop-helix (bHLH) transcription factor that has been known to be essential for proper gastrulation mesoderm formation, and neural crest migration (15). Intriguingly, increased TWIST expression is detected in metastatic breast cancer cells and is required for EMT and breast cancer metastasis (11). Role of TWIST in EMT has also been reported in other cancer types, including those of prostate (16) and uterus (17). High TWIST expression further correlates with tumor invasion and metastasis in breast carcinomas (11), esophageal squamous cell carcinomas (18), and gliomas (19). A recent study reported that STAT3 knockdown of mouse 4T1 mammary tumor cells led to altered expression of several genes, including those of activated src, phosphorylated Akt, c-Myc, and Twist, but not p53 nor total src (20). How mouse STAT3 knockdown led to reduced phosphorylation of src and Akt remains unknown. Whereas c-Myc is a known STAT3 target gene, mouse *Twist* has yet been shown to be a direct transcriptional target of STAT3. STAT-binding sites are not found in the mouse *twist* gene promoter, suggesting its expression reduction by STAT3 small interfering RNA was likely due to indirect effects. As for the human *TWIST* gene, its transcriptional regulation is yet investigated.

Given the association between EGFR overexpression and high metastatic potential, we speculate that the EGF/EGFR pathway promotes EMT via activation of EMT mediators, such as TWIST, SLUG, and Snail. Our initial examination of a breast cancer cell line, MDA-MB-468, indicated that TWIST is expressed at a higher level

**Note:** Current address for H-W. Lo: Department of Surgery (Box 3156), Duke University School of Medicine, 103 Research Drive, Durham, NC 27710.

**Requests for reprints:** Mien-Chie Hung, Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3668; Fax: 713-794-0209; E-mail: mhung@mdanderson.org.

©2007 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-07-0575

compared with SLUG and Snail, which prompted us to further investigate the regulatory role of the EGF/EGFR pathway in TWIST expression and in TWIST-mediated EMT. Here, we report that EGF treatment and EGFR expression are important for TWIST expression. However, unexpectedly, we also found that the underlying mechanisms involve transcriptional regulation of TWIST by STAT3, an oncprotein constitutively activated in many human cancers and implicated in tumor progression (21–23). The information derived from these studies provides critical insights into the regulation of TWIST gene expression and into the biology of tumors with deregulated EGFR and STAT3 pathways and is important in the management of metastatic tumors.

## Experimental Procedures

**Cell lines and cell culture.** A431 human epidermoid carcinoma cells, MDA-MB-468 human breast carcinoma cells, and EGFR-null Chinese hamster ovary (CHO) cells and Madin-Darby canine kidney (MDCK) epithelial cells were obtained from American Type Culture Collection. CHO-NEO, CHO-EGFR, and CHO-EGFR-NLS stable cells were derived from the parental CHO cells as previously described (24). HER5 cells are stable EGFR transfectants of Swiss 3T3 cells, and NR-6 cell line is an EGFR-null Swiss 3T3 variant. All cells were maintained in DMEM supplemented with 10% FCS, except that CHO-NEO, CHO-EGFR, and CHO-EGFR-NLS stable lines were supplemented with 1 mg/mL G418 additionally. PANC28 human pancreatic cancer cell line was a kind gift from Dr. Paul Chiao at the University of Texas M. D. Anderson Cancer Center.

**Chemicals, plasmids, and mammalian transfection.** PD158780, AG490, AG1478, and the PI3K inhibitor LY294002 were obtained from Calbiochem Corp. The specific MEK/ERK inhibitor U0126 was purchased from Promega. Iressa was purchase from AstraZeneca Pharmaceuticals. Purified EGF, transforming growth factor- $\alpha$  (TGF- $\alpha$ ), HB-EGF, and all other chemicals were from Sigma-Aldrich. Transfection was carried out by a cationic liposome, SN, as previously described (25). EGFR expression vector, pcDNA3.1-EGFR, was a kind gift from Dr. David James (University of California, San Francisco, San Francisco, CA). Dominant-negative STAT3-expression vector (pCAGGS-STAT3F), which carries the mutation Y705F and constitutively active STAT3-expression plasmid (pRC-STAT3C-flag), was kindly provided by Dr. Keping Xie (M. D. Anderson Cancer Center). Control small interfering RNA and STAT3 small interfering RNA were obtained from Millipore/Pharmacon.

**Reverse transcription-PCR.** In these studies, cancer cells of exponential growth were starved for serum for 24 h and stimulated with EGF (100 ng/mL) for 0, 1, and 2 h. Cells were harvested, and total RNA was extracted using the SV total RNA isolation system kit (Promega). Extracted total RNA was then subjected to reverse transcription using reverse transcriptase (Invitrogen) to generated first-strand cDNA using the oligo dT primer. PCR was then carried out for 30 cycles, and each cycle was with 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min. Primers with sequences 5'-TTAGCACCCCTGGCCAAGG-3' and 5'-CTTACTCCTGGAGGC-CATG-3' were used for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). For TWIST, primers 5'-GGAGTCCGAGTCTTACGAG-3' and 5'-TCTGGAGGACCTGG TAGAGG-3' were used in PCR. For SLUG, primers 5'-TGATGAAGAGGAAAGACTACAG-3' and 5'-GCTCACATATTCTTGTCACAG-3' were used in the PCR reactions. Primers 5'-CGAAAGG CCTTCAACTGCAAAT-3' and 5'-ACTGG-TACTTCTGACATCTG-3' were used to generate Snail PCR products. For real-time PCR, SYBR-Green Master PCR mix was

used in the iCycler system (Bio-Rad) in triplicates as previously described (24). All quantification was normalized to an endogenous control GAPDH. The PCR program was 95°C for 4 min, followed by 40 cycles of 95°C for 15 s and 60°C for 45 s.

**Western blot analyses.** Western blot analyses were done as previously described (24, 26). The antibodies used for these studies included rabbit polyclonal EGFR, TWIST, and STAT3 antibodies and goat polyclonal Snail antibody, which were purchased from Santa Cruz Biotech. Rabbit polyclonal phosphorylated STAT3 (p-STAT3; Y-705), phosphorylated EGFR (Y-1045), and Akt/phosphorylated Akt antibodies were from Cell Signaling. Additional antibodies used for Western blot were mouse monoclonal  $\beta$ -actin and  $\alpha$ -tubulin (Sigma), E-cadherin (BD Pharmigen), ERK/phosphorylated ERK (Upstate), fibronectin (NeoMarkers), and vimentin (NeoMarkers) antibodies.

**Construction of the human TWIST promoter-driven luciferase reporter constructs.** The human genomic TWIST plasmid was a kind gift from Dr. Vincent J. Cristofalo (Allegheny University of the Health Science, Philadelphia, PA). The full-length human TWIST promoter was amplified from the genomic TWIST plasmid to contain the promoter region up to nt –824 using forward primer 5'-CGTGCTAGCATTGGACTGGGTTCC-3' and reverse primer 5'-AGTAAGCTTGGAGTTGGCGAGAG-3'. The PCR product was digested with NheI and HindIII and subsequently cloned to the pGL-3 basic luciferase reporter vector (Promega), and positive clone was designated phTWIST-824. The reverse primer was used to generate other TWIST promoter segments. For phTWIST-604, phTWIST-120, and phTWIST-94 constructs, forward primers 5'-CGTGCTAGCGTTGGCCTTT GGAAC-3', 5'-CGTGCTAGCAAAC-TTCCTATAAAC-3', and 5'-CGTGCTAGCTCCCTCCTCCTCA-CGT-3' were used, respectively. To generate the phTWIST-120/MA mutant, forward primer 5'-AAACTTCCCTATAAAACTTCGG-CCGGTCCCTCCTCC-3' and reverse primer 5'-GGAGGGACCGG-CCGAAGCCCCATAGGAAAGTTT-3' were used. To generate the phTWIST-120/MB mutant, we used forward primer 5'-CGCGTGCT-AGCAAACGGGCCTATAAAACTTCGAAAAG-3' and reverse primer 5'-CTTTTCGAAGTTTATAGGCCGTTGCTAGCACGCG-3'. Site-directed mutagenesis was done as previously described (24). All constructs were subjected to DNA sequencing to confirm no PCR-generated artifacts.

**Mammalian transfection and luciferase assay.** Cells were transfected using the cationic liposome method using SN as described previously (25) or Fugene HD (Roche). pRL-TK (Promega) was cotransfected as a control for transfection efficiency. After transfection and experiment treatments, cells were lysed and luciferase activity was measured using Dual Luciferase kit (Promega) according to manufacturer's instructions (27, 28).

**Biotinylated oligonucleotide precipitation assays/oligo pull-down assay.** These studies were done as described previously (24, 29). The nucleotide sequences of biotinylated oligonucleotides corresponding to TWIST-120, TWIST-120/MA, and TWIST-120/MB are 5'-AAACTTCCCTATAAAACTTCGAAAAGTCCCTCCTCC-3', 5'-AAACTTCCCTATAAAACTTCGGCCGGTCCCTCCTCC-3', and 5'-AAACGGGCCTATAAAACTTCGGCCGGTCCCTCCTCC-3', respectively. A functional STAT3-binding site [acute-phase response element (APRE)], known to bind to STAT3/APR factor (30, 31), was used as the positive control for STAT3 binding and was designated as STAT3-BS. The sequence for STAT3-BS is 5'-GATCCTCTGGAAATTCTAGATC-3'. After annealing complementary strands (1  $\mu$ g), binding reactions were carried out at 4°C for 16 h to include 6.5  $\mu$ g nuclear extracts isolated from the control

and EGF-stimulated MDA-MB-468 cells. Protein-bound probe was precipitated using ImmunoPure streptavidin-agarose beads (Pierce), washed, and subjected to detection of p-STAT3 and EGFR via Western blot analyses as described earlier.

**Chromatin immunoprecipitation assay.** This procedure was done as described previously (24, 32). In brief, MDA-MB-468 cells were serum-starved overnight and treated without and with EGF (100 ng/mL) for 30 min. The cells were cross-linked with 1% formaldehyde at room temperature for 10 min, and the reaction was stopped by the addition of glycine to a final concentration of 0.125 mol/L. After washing twice with ice-cold PBS, the cells were scraped off the plate, centrifuged, and resuspended in 400  $\mu$ L of cell lysis buffer [5 mmol/L Tris-HCl (pH 8.0), 85 mmol/L KCl, 0.5% NP40, 1  $\mu$ g/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride (PMSF)]. After incubation on ice for 10 min, the cells were dounced to isolate nuclei, and the nuclei were collected, resuspended in 200  $\mu$ L nuclei lysis buffer [50 mmol/L Tris-HCl (pH 8.1), 10 mmol/L EDTA, 1% SDS, 1  $\mu$ g/mL aprotinin, and 1 mmol/L (PMSF), and sonicated 4 pulses for 10 s each. After centrifugation, the supernatant was diluted 1:10 with immunoprecipitation dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mmol/L EDTA, 16.7 mmol/L Tris-HCl (pH 8.0), 167 mmol/L NaCl, 1  $\mu$ g/mL aprotinin, and 1 mmol/L PMSF]. The cell lysates were precleared with normal IgG and protein A-agarose beads and subjected to immunoprecipitation with mouse monoclonal anti-EGFR antibody (Ab-13; NeoMarkers), polyclonal anti-STAT3 antibody (C-20; Santa Cruz Biotechnology), or normal IgG at 4°C overnight. Immunoprecipitated complexes were collected by adding salmon sperm DNA/protein A-agarose (Upstate) for 15 min at 4°C. Immunoprecipitates were washed twice with dialysis buffer [2 mmol/L EDTA, 50 mmol/L Tris-HCl (pH 8.0)] and four times with immunoprecipitation wash buffer [0.5 mol/L LiCl, 1% NP40, 1% sodium deoxycholate, 100 mmol/L Tris-HCl (pH 8.0)]; the DNA/protein complex was eluted twice using elution buffer (50 mmol/L NaHCO<sub>3</sub>, 1% SDS) and treated with RNase A for 30 min at 37°C. The protein/DNA cross-links were reversed by heating at 65°C for 16 h, and then the DNA were extracted using QIAquick PCR purification kit (Qiagen). For PCR, 3  $\mu$ L from a 40- $\mu$ L DNA preparation was used for amplifications. Specific sequences of the human TWIST promoter in the immunoprecipitates were detected by PCR with primers forward 5'-AGTCTCCTCCGACCCTTCCTG -3' and reverse 5'-CTCCGTGCAGGCAGGAAAGTTGG -3'. The resulting PCR product spans the -364 to -33 region that includes the putative STAT3-binding sites. The c-fos promoter has been previously shown to bind to nuclear EGFR and STAT3 and thus also was amplified as positive controls (24).


**Immunohistochemical analyses, histologic scoring, and statistical analyses.** The cohort of primary breast carcinoma specimens, previously stained for EGFR and iNOS, was consisted of 130 cases (24, 26). Immunohistochemical staining was done as previously described (24, 26). In this study, rabbit polyclonal TWIST and p-STAT3 (Y705) antibodies from Santa Cruz Biotech and Cell Signaling, respectively, were used. The immunoreactivity for TWIST was semiquantitatively scored using a well-established system in which H score was generated by incorporating both the percentage of positive tumor cells and the intensity of staining (33). All slides were independently viewed and scored by two pathologists (W.X. and Y.W.). Slides in which there was a scoring discrepancy of >10% were reevaluated and reconciled on a two-headed microscope. Statistica 6.0 (Statsoft) and regression analysis were used to analyze the correlation.

## Results

**EGF exposure induces transition of the epithelial to the mesenchymal-like phenotype in cultured breast cancer cells.** Cancer cells of epithelial origin undergo EMT as an early event that leads to local invasion and metastasis to distant sites. Despite accumulating studies showing a positive link between high EGFR expression and cancer invasion/metastasis, the specific involvement of EGFR in EMT remains elusive. We, therefore, aimed to examine whether EGF stimulation induces EMT in cancers of the breast and pancreas, two epithelial cancers that can invade and metastasize. This is also important as the survival rate for metastatic breast cancer was reported to be only 9.1% to 14.7% between 1991 and 1995 (34). As indicated in Fig. 1A, the human breast carcinoma MDA-MB-468 cells maintained in a minimal amount (0.5%) of FCS (a) retained the epithelial morphology, whereas those supplemented with EGF (b) and TGF- $\alpha$  (c) displayed mesenchymal-like morphology after 5-day treatments. Approximately, 500 cells were examined for each treatment, and three independent experiments were carried out. Similar observations were found in human pancreatic cancer cells PANC28 and A431 human epidermoid carcinoma cells (data not shown). Both cell lines express EGFR (Fig. 2). We next examined whether E-cadherin repressors, TWIST, SLUG, and Snail may play a role in EGF-induced EMT in MDA-MB468 cells. Using reverse transcription-PCR (RT-PCR), we found that MDA-MB-468 cells express detectable levels of TWIST and Snail transcripts, but not that of SLUG (Fig. 1B). Western blot analyses further showed that these cells contained high levels of TWIST protein, but not Snail, and that EGF enhanced TWIST protein expression (Fig. 1C). In fact, Snail expression was very low, and the signals became visible only after prolonged autoradiography. Together, these results suggest that EGFR ligands EGF and TGF- $\alpha$  induce EMT-like morphologic changes in human cancer cells, and among the three transcriptional repressors for E-cadherin, TWIST is the only one that expresses at a detectable level and also responds to EGF stimulation.

**EGF induces expression of TWIST and mesenchymal markers, as well as reduction of an epithelial marker.** TWIST, a bHLH transcription factor and repressor of E-cadherin expression, is frequently detected in metastatic cancer cells and is required for EMT and breast cancer metastasis (11, 16, 18). To date, human *TWIST* gene regulation remains largely unknown. To determine whether EGF/EGFR promotes EMT via TWIST, we first examined the effect of EGF treatment on the human *TWIST* gene transcription in EGFR-expressing MDA-MB-468 (Fig. 2A) and human epidermoid carcinoma A431 cells (Fig. 2B). After serum starvation for 24 h, EGF significantly increased *TWIST* gene transcripts at 2 h, as indicated by RT-PCR (left) and quantitative real-time PCR (right). Expression of GAPDH served as a loading control. Consistently, EGF stimulation increased the levels of TWIST protein in a panel of EGFR-expressing cancer cells, including MDA-MB-468, A431, and PANC28 (Fig. 2C, left). EGFR in the PANC28 cells seem to undergo down-regulation after EGF treatment as expected. In contrast, EGFR-overexpressing MDA-MB-468 and A431 cells contain sustained levels of EGFR. This observation is consistent with the notion that overexpression of EGFR undergoes faster recycling and impairs its down-regulation due to limiting levels of regulatory molecules that mediate rapid endocytosis and lysosomal targeting EGFR (35, 36). Interestingly, EGFR-null CHO-NEO and NR-6 cells do not contain detectable levels of TWIST, and forced EGFR expression in these cells induced TWIST expression (Fig. 2C, middle and right).

**Figure 1.** EGF exposure induced transition of the epithelial to the mesenchymal-like phenotype in cultured breast cancer cells. Human breast carcinoma MDA-MB-468 cells were used in these studies. Three independent experiments were done. Cancer cells were serum-starved for 24 h before treatments. *A*, EGF-treated MDA-MB-468 cells displayed mesenchymal morphology. Cells were treated with 0.5% FCS only (*a*), 0.5% FCS with 50 ng/mL EGF (*b*), and 0.5% FCS with 50 ng/mL TGF- $\alpha$  (*c*). Cell morphology was examined and photographed daily using a phase-contrast microscope. At day 5, unstimulated MDA-MB-468 cells retained their epithelial phenotype (*a*). In contrast, cells treated for 5 d with EGF (*b*) and TGF- $\alpha$  (*c*) displayed detached mesenchymal-like morphology. *B*, transcripts of EMT mediators, TWIST and Snail, were detected. Total RNA was isolated and subjected to RT-PCR to detect TWIST, SLUG, Snail gene transcripts. Expression of GAPDH serves as a loading control. *C*, TWIST, but not Snail, protein was expressed at high levels. Cancer cells were starved for 24 h and treated without and with EGF for 6 h; total cell lysates were extracted and subjected to Western blot analyses for expression of TWIST and Snail. Note the exposure time to detect the expression of Snail was 5 times longer than that of TWIST.



CHO-EGFR and Her5 are stable lines derived from parental CHO and NR-6 cells, respectively, to express high levels of EGFR, as reported previously (37).

In addition to EGF, other EGFR ligands, HB-EGF and TGF- $\alpha$ , similarly activated the human TWIST gene expression in MDA-MB-468 cells (Fig. 2D, *left*), which is consistent with their implication in tumor invasion (38). Consistent with the phenotypic observation in Fig. 1, chronic EGF exposure reduced expression of E-cadherin, an epithelial marker, and increased levels of vimentin and fibronectin, mesenchymal markers (Fig. 2D, *right*). At day 5 post-EGF stimulation, both EGFR-expressing MDA-MB-468 and A431 cells expressed significantly more TWIST compared with the untreated controls. Taken together, these data indicate that EGF/TGF- $\alpha$  stimulation and EGFR expression are important for the human TWIST gene expression and that EGF induced gene expression changes typically found in cancer cells undergoing EMT.

**EGFR-induced TWIST expression involves STAT3.** Because EGF/EGFR can activate many signaling modules to regulate gene expression, we then asked via which downstream pathways the human TWIST gene becomes activated. To address this, we pretreated MDA-MB-468 cells with inhibitors to EGFR (Iressa and AG1478), Janus-activated kinases (JAKs)/STATs (AG490), PI3K/Akt (LY294002), and MEK/ERK (U0126) and examined TWIST's response to EGF stimulation. The results (Fig. 3A) suggest that EGF-induced TWIST expression requires EGFR and STAT3, but not those of PI3K/Akt and MEK/ERK. Effectiveness of all inhibitors is indicated by sufficient suppression of target kinases. Consistently, time course studies in Fig. 3B and C showed a concurrent TWIST expression and STAT3 activation (Y705 phosphorylation) after EGF/TGF- $\alpha$  treatment in MDA-MB-468 and normal epithelial MDCK cells. These experiments were done thrice; band signals were quantified by NIH ImageJ software, and the correlation ( $R$ )


and  $P$  values between p-STAT3 and TWIST were determined by regression analyses. These results suggest that EGFR up-regulates the human TWIST gene expression, which seems to require STAT3 activation.

**EGFR and STAT3 activate the human TWIST gene promoter.** STAT3 is a DNA-binding transcription factor that elicits its physiologic function by transcriptionally regulating gene expression after activation by cytokines and growth factors signal pathways (39, 40). STAT3 becomes phosphorylated at Y705, then activated by cell-surface EGFR, and has been found to be constitutively activated in many cancers and to involve in tumorigenesis and metastasis (41–43). Given the association of STAT3 with invasive phenotype, we further aimed to examine whether STAT3 is important in activating the human TWIST gene expression at the transcriptional level. To this end, we generated the human TWIST promoter-driven luciferase constructs that contain 824, 604, and 120 bp of the promoter and designated them as pH\_TWIST-824, pH\_TWIST-604, and pH\_TWIST-120, respectively. Relative luciferase activity was derived from firefly luciferase activity after normalization against the activity of the transfection efficiency control Recilla luciferase. As indicated in Fig. 4A, all three EGFR ligands (EGF, TGF- $\alpha$ , and HB-EGF) significantly activated the human TWIST promoter. Interestingly, the pH\_TWIST-120 construct showed similar extents of EGF responsiveness to the pH\_TWIST-604 plasmid, indicating that the critical DNA elements are within the  $-120$  bp region of the promoter. Using EGFR-null CHO and NR-6 cells, we found that reexpression of EGFR and expression of constitutive STAT3 (STAT3CA) activated the TWIST-120 promoter (Fig. 4B). Coexpression of EGFR and STAT3CA achieved the highest level of induction compared with single expression (Fig. 4B, *left*). In CHO-EGFR cells, STAT3CA significantly induced TWIST-120 promoter activation, whereas STAT3-DN reduced the promoter

activity (Fig. 4B). Consistently, EGFR kinase inhibitors (Iressa and PD158780) and JAKs inhibitor (AG490) reduced the activity of the *TWIST* gene promoter. Furthermore, forced expression of dominant-negative STAT3 reduced *TWIST* expression (Fig. 4C, left). Consistently, STAT3 expression knockdown by STAT3 small interfering RNA, but not by the control small interfering RNA, reduced *TWIST* expression (Fig. 4E, right). Together, these data indicate an important role of STAT3 in EGFR-mediated *TWIST* gene expression.


As we recently found that nuclear EGFR contains transcriptional activity and activates expression of cyclin D1, iNOS, and B-Myb

(24, 28, 32), we then examine the involvement of nuclear EGFR in EGF-induced *TWIST* gene activation. Using isogenic lines CHO-NEO, CHO-EGFR, CHO-EGFR-NLS (CHO with the nuclear entry-defective EGFR), we found that EGFR-NLS mutant displayed a constitutive *TWIST* promoter activity but failed to respond to EGF (Fig. 4D). Although the EGF responsiveness of EGFR-NLS/CHO seems to favor that nuclear localization of EGFR might be involved in the STAT-mediated *TWIST* up-regulation. This notion is not supported by the fact that EGFR-NLS can constitutively activate *TWIST* promoter (Fig. 4D). Thus, further investigation is required for a role of direct nuclear EGFR in the *TWIST* up-regulation.



**Figure 2.** EGF stimulation induces expression of *TWIST* and mesenchymal markers, as well as reduction of an epithelial marker. *A* and *B*, EGF increases *TWIST* transcription in EGFR-expressing cancer cells. MDA-MB-468 (human breast carcinoma cells in *A*) and A431 (human epidermoid carcinoma cells in *B*) were serum-starved for 24 h, exposed to EGF (100 ng/mL) for 0, 1, and 2 h, and harvested. Total RNA was isolated and subjected to RT-PCR (left) and quantitative real-time PCR (right). Expression of GAPDH serves as a loading control. *C*, EGF stimulation induces expression of *TWIST*. All cells were serum-starved for 24 h and exposed to EGF (100 ng/mL) for 6 h, and total lysates were extracted. Expressions of *TWIST*, EGFR, and β-actin were examined using Western blot analyses. Left, EGF stimulation increased *TWIST* expression in EGFR-expressing cancer cells. A panel of EGFR-expressing cancer cell lines were used in these studies including MDA-MB-468 (human breast carcinoma), A431 (human epidermoid carcinoma), and PANC28 (human pancreatic cancer). Middle and right, forced EGFR expression in EGFR-null cells induce *TWIST* reexpression. CHO-NEO (middle) and NR-6 (rat fibroblasts; right) are EGFR-null, whereas CHO-EGFR and Her5 are stable lines which express EGFR. As expected, EGFR in the PANC28 cells seem to undergo down-regulation after EGF treatment, whereas those in EGFR-overexpressing MDA-MB-468 and A431 cells displayed reduced degradation (36). *D*, EGFR ligands HB-EGF and TGF-α activate *TWIST* gene expression (left). MDA-MB-468 cells were treated without or with HB-EGF (100 ng/mL) and TGF-α (100 ng/mL) for 6 h and harvested; total cell lysates were extracted and subjected to Western blot analyses. Right, Prolonged EGF treatment reduced expression of E-cadherin and increased that of vimentin, fibronectin, and *TWIST*. MDA-MB-468 and A431 cells were treated without or with EGF (100 ng/mL) for 5 d and harvested; total cell lysates were extracted and subjected to Western blot analyses for expression of *TWIST*, the epithelial marker E-cadherin and mesenchymal markers, vimentin and fibronectin.

**Figure 3.** EGF-induced TWIST expression involves EGFR and STAT3. *A*, EGFR and STAT3 inhibitors suppressed TWIST expression. Serum-starved MDA-MB-468 cells were pretreated for 1 h without and with various inhibitors including Iressa (EGFR; 5  $\mu$ mol/L), AG1478 (EGFR; 10  $\mu$ mol/L), AG490 (JAKs/STATs; 10  $\mu$ mol/L), LY294002 (PI3K/Akt; 20  $\mu$ mol/L), and U0125 (MEK/ERK; 10  $\mu$ mol/L). Cells were then stimulated with EGF (100 ng/mL) for 5 h, harvested, and subjected to Western blot analysis. Levels of TWIST were determined. Efficiency of various inhibitors was indicated by reduced phosphorylation of EGFR (for Iressa and AG1478), STAT3 (for AG490), Akt (for LY294002), and ERK (for U0125). *B*, time-dependent correlation between TWIST expression and STAT3 activation in breast cancer cells. Serum-starved MDA-MB-468 cells were treated with EGF (100 ng/mL) for 0, 1, 2, and 4 h and harvested for Western blot analysis. Levels of TWIST expression, total STAT3, and p-STAT3 at Y705 (p-STAT3) were determined. These experiments were repeated thrice, and bands were quantified using the NIH ImageJ software. Regression analysis was then done to determine the correlation between p-STAT3 and TWIST. *C*, time-dependent correlation between TWIST expression and STAT3 activation in normal epithelial cells. MDCK epithelial cells were serum-starved and stimulated with EGF (100 ng/mL) and TGF- $\alpha$  (100 ng/mL) for 0, 1, 2, 4, 6, and 24 h. Harvested cells were examined, via Western blot analysis, for expression of TWIST, p-STAT3 (Y705), STAT3, and  $\alpha$ -tubulin. These experiments were repeated thrice, and signals were quantified using ImageJ (NIH). Regression analysis was then conducted to determine the correlation between p-STAT3 and TWIST.




**Identification of STAT3-targeted region within the human *TWIST* promoter.** We found, thus far, that STAT3 is involved in EGFR-induced *TWIST* gene activation and that a 120-promoter region may be important in this involvement (Fig. 4). Next, we asked whether the *TWIST* gene promoter contains STAT3-binding sites. As illustrated in Fig. 5A, the proximal region (−120 bp) of the human *TWIST* promoter contains two putative STAT3-binding sites. A TATAA box is located at −32 to −28 bp, relative to the transcription start site. To analyze the functionality of the putative STAT3-binding sites A (−116 to −107) and B (−103 to −96), we did site-directed mutagenesis to generate the phTWIST-120/MA mutant with nucleotide substitutions (underlined) at −116 to −104 bp region and the phTWIST-120/MB mutant with nucleotide changes (underlined) at nt −99 to −96. Additionally, the pTWIST-94 was generated to remove the putative STAT3-binding sites and

thus only contains the minimal promoter up to −94 bp. Using these reporters, we found that mutation at either putative STAT3-binding site, A or B, reduced but did not abolish the ability of the human *TWIST* promoter to respond to EGFR ligands in MDA-MB-468 cells (Fig. 5B, left). Deletion of the STAT3-binding sites reduced its basal level of promoter activity and rendered EGFR-irresponsiveness of the *TWIST* promoter, as indicated by the failure of the phTWIST-94 construct to respond to EGF/TGF- $\alpha$  (Fig. 5B, right).


We further examined the ability of p-STAT3 to bind to the putative STAT3-binding site within the human *TWIST* promoter using the biotinylated oligonucleotide precipitation/oligo pull-down assay. As indicated in Fig. 5C, EGF activated the binding of p-STAT3 to the consensus STAT3-binding site (STAT3-BS/APRE; refs. 30, 31), the putative STAT3-binding site in the *TWIST* promoter,

the TWIST-120/MA and TWIST-120/MB oligonucleotides. Consistent with low EGF responsiveness of the TWIST-120/MB promoter (Fig. 5B, left), the TWIST-120/MB fragment was found to contain lowest binding affinity to p-STAT3 (Fig. 5C). We did not detect binding of nuclear EGFR to any biotinylated oligonucleotides that we tested. Furthermore, we examined whether nuclear STAT3 binds to the TWIST gene promoter using the *in vivo* protein-DNA

binding chromatin immunoprecipitation (ChIP) assay, and the results are shown in Fig. 5D. Upon EGF stimulation, nuclear STAT3 binds to the human *TWIST* gene promoter. In contrast, nuclear EGFR did not associate with the *TWIST* promoter at a detectable level, consistent with the lack of EGFR binding observed in Fig. 5C. As expected, both nuclear EGFR and STAT3 bind to the c-fos promoter in an EGF-dependent fashion, as we previously reported



**Figure 4.** EGFR and STAT3 activate the human *TWIST* gene promoter. The human *TWIST* promoter-driven luciferase constructs were engineered to contain 824, 604, and 120 bp of the promoter and designated as phTWIST-824, phTWIST-604, and phTWIST-120, respectively. All transfection and determination of luciferase activity were carried out as previously described (24). Relative luciferase activity was derived from firefly luciferase activity after normalization against the activity of the transfection efficiency control, Recilla luciferase. All data represent the mean and SD from at least three independent experiments. *A*, EGFR activation by various ligands induces the *TWIST* gene promoter. MDA-MB-468 cells in six-well culture plates were transfected with phTWIST-824, phTWIST-604, and phTWIST-120. Recilla luciferase construct was cotransfected as transfection controls. After 24 h, transfected cells were serum-starved for 20 h and stimulated with 100 ng/mL EGF, TGF- $\alpha$ , and HB-EGF for 4 h. Harvested cells were lysed and subjected to luciferase assay. *B*, expression of EGFR and constitutive STAT3 (STAT3CA) activate the *TWIST* promoter. EGFR-negative CHO-NEO cells (left) were cotransfected with phTWIST-120 and expression plasmids, pEGFR, pSTAT3CA, or combination. EGFR-negative NR-6 cells (middle), rat fibroblasts, were cotransfected with pEGFR and pSTAT3CA. After 48 h, transfected cells were lysed and luciferase activities determined. Right, CHO-EGFR cells were cotransfected with phTWIST-120 and indicated plasmids (pSTAT3CA and pSTAT3-DN). At 48 h, serum-starved cells were stimulated with EGF (100 ng/mL) for 4 h. Additionally, aliquots of CHO-EGFR cells were transfected with phTWIST-120, serum-starved, and pretreated with EGFR inhibitors (Iressa, 5  $\mu$ mol/L; PD158780/PD, 10  $\mu$ mol/L) and Jak/STAT3 inhibitor (AG490, 10  $\mu$ mol/L) before 4 h of EGF stimulation. Control phTWIST-120 transfected cells were treated with EGF (Mock) for 4 h before analysis for luciferase activity. *C*, forced expression of dominant-negative STAT3 (STAT3-DN) and STAT3 small interfering RNA reduced *TWIST* expression. Left, MDA-MB-468 cells were transfected with control and STAT3-DN vectors and, 48 h later, harvested and subjected to Western blot analysis for *TWIST* and  $\alpha$ -tubulin expression. Right, Forced expression of STAT3 small interfering RNA reduced *TWIST* expression. MDA-MB-468 cells were transfected with control small interfering RNA [nonspecific (N.S.), small interfering RNA, and STAT3 small interfering RNA]. After 48 h, transfected cells were harvested and subjected to Western blot analysis for STAT3, *TWIST*, and  $\beta$ -actin expression. *D*, involvement of nuclear EGFR in EGF-responsiveness of the human *TWIST* gene promoter. CHO-NEO, CHO-EGFR, CHO-EGFR-NLS cells were transfected with phTWIST-120, serum-starved at 24 h posttransfection, and treated with 100 ng/mL EGF and TGF- $\alpha$  for 4 h. Harvested cells were lysed and subjected to luciferase assay.



**Figure 5.** Identification of STAT3-targeted region within the human *TWIST* promoter. *A*, schematic illustration of the proximal region of the human *TWIST* promoter. The human *TWIST* proximal promoter contains two putative STAT3-binding elements. A TATAA box is located at nt –32 to –28, relative to the transcription start site. Site-directed mutagenesis was done to generate the phTWIST-120/MA mutant that contains multiple nucleotide substitutions (*underlined*) at nt –116 to –107 region and the phTWIST-120/MB mutant with nucleotide changes (*underlined*) at nt –99 to –96. The pTWIST-94 was additionally generated to remove the putative STAT3-binding sites and thus contains the minimal promoter up to –94 bp. *B*, mutation at the putative STAT3-binding site II significantly reduced the ability of the human *TWIST* promoter to respond to EGFR ligands. MDA-MB-468 cells were transfected with phTWIST-120, pTWIST-94, phTWIST-120/MA, and phTWIST-120/MB as previously described. After 48 h, serum-starved transfected cells were stimulated with EGF (100 ng/mL) for 4 h before determination of luciferase activities. All data represent the mean and SD from three independent experiments. *C*, biotinylated oligonucleotides precipitation assay. These studies were done to determine the degree of the binding of STAT3 to the *TWIST* promoter fragments. MDA-MB-468 cells untreated and treated with EGF (100 ng/mL) for 1 h were harvested, and nuclear lysates were extracted. Nuclear extracts were then subject to binding affinity evaluation to a number of biotinylated oligonucleotides, namely, STAT3-BS/APRE (30, 31), TWIST-120/TWIST, TWIST-120/MA, and TWIST-120/MB. Biotinylated oligos were then precipitated by avidin beads, washed and subjected to Western blot analysis for p-STAT3 and EGFR. *D*, nuclear STAT3, but not nuclear EGFR, binds to the human *TWIST* gene promoter. A431 cells were serum-starved and stimulated without and with EGF (100 ng/mL) for 30 min and subjected to the *in vivo* binding assay ChIP, as we previously described. Briefly, EGFR monoclonal antibody (Neomarkers, Ab13) and STAT3 polyclonal antibody (Santa Cruz, C-20) were used in immunoprecipitation. IgG was used as negative control for immunoprecipitation, whereas input chromatin was used as positive controls for PCR and for equal loading. The c-fos promoter was also amplified as a positive control for both EGFR and STAT3 binding.

(24). The IgG was used in immunoprecipitation as negative controls and did not yield any band signals, indicating the assay specificity. Input chromatin was also used in these assays to indicate that equal amounts of cell lysates were used from the –EGF and +EGF treatment groups. In summary, we identified and functionally characterized the STAT3-targeted region within the human *TWIST* promoter.

**Positive correlations between EGFR/p-STAT3 and TWIST in a cohort of primary breast carcinomas.** We revealed using cultured cells that EGFR activates the human *TWIST* gene expression via activation of STAT3. Next, we aimed to examine whether such regulation also exists in the primary tumor specimens from cancer patients. To this end, we analyzed *TWIST* expression via immunochemical staining analysis in a cohort of primary breast carcinomas that have been previously immunostained for EGFR and p-STAT3 (24, 26). Two pathologists

independently viewed and scored all slides. All statistical analyses were done using Statistica 6.0 software. Regression analysis indicated a positive correlation between non-nuclear EGFR and *TWIST* ( $P = 0.01$ ). Levels of nuclear EGFR do not significantly correlate with those of *TWIST* ( $P = 0.6$ ), which is in agreement with the findings in Fig. 5C and D. To further investigate whether p-STAT3 correlates with *TWIST* expression, we immunostained the same cohort of tumors for p-STAT3 and analyzed the correlation between p-STAT3 and *TWIST*. We found that levels of *TWIST* correlates significantly with those of p-STAT3 ( $R = 0.28$ ,  $P = 0.0013$ ; Fig. 6C, *left*). In agreement with the role of EGFR as an upstream activator of STAT3, we found a significant, positive correlation between non-nuclear EGFR and p-STAT3 ( $R = 0.35$ ,  $P = 0.00003$ ; Fig. 6C, *right*). Furthermore, Fig. 6D shows two representative tumors in which the upper case contains high EGFR/p-STAT3/*TWIST* and the lower tumor contains low EGFR/p-STAT3/*TWIST*.


Together, we reported here that levels of EGFR and p-STAT3 correlate positively with those of the *TWIST* gene in breast carcinomas.

## Discussion

Metastasis is a major obstacle for cancer therapy and is a primary cause of mortality in many cancers, including that of the breast. Understanding the biology of cancer cells with high metastatic potential is, therefore, important in identifying tumors that are likely to undergo metastasis and in improving current anticancer therapy. It has been shown that cancers with the deregulated EGFR pathway possess a high likelihood for local invasion and subsequent metastasis. The specific involvement of EGFR in EMT, an event that takes place during the early stage of tumor invasion, intravasation, and subsequent metastasis to the distant organ sites, remains elusive. The current study was thus

undertaken to examine the role of aberrant EGFR pathway in EMT. Here, we report that cancer cells with high EGFR expression/activity undergo EGF/TGF- $\alpha$ -induced EMT, and this phenotypic transition involves EGFR-mediated activation of STAT3 and subsequent STAT3-activated *TWIST* gene expression.

*TWIST* is a bHLH transcription factor that has been known as an essential player for proper gastrulation mesoderm formation and neural crest migration (15). More recently, *TWIST* has been found to express at high levels in a number of human tumors, including those of the breast, prostate, esophagus, lung, uterus, skin, liver, and brain (16–19, 44–46). Importantly, increased *TWIST* expression is associated with breast cancer metastasis to the lung and increased EMT and intravasation (11). Correlative studies further indicate an association of high *TWIST* expression with invasion and therapeutic response in other cancer types (17–19, 44, 47–49). Despite frequent reports of *TWIST* overexpression in human cancers, transcriptional regulation of the human *TWIST* genes is



**Figure 6.** Positive correlations between non-nuclear EGFR/p-STAT3 and *TWIST* in a cohort of primary breast carcinomas. The cohort of primary breast carcinoma specimens, previously stained for p-STAT3 (Y705) and *TWIST* expression via immunochemical staining analysis. All slides were independently viewed and scored by two pathologists. When the scoring discrepancy is  $>10\%$ , slides were reevaluated and reconciled by two pathologists on a two-headed microscope. All statistical analyses were done using Statistica 6.0 software. *A*, positive correlation between non-nuclear EGFR and *TWIST*. Levels of *TWIST* were correlated with those of non-nuclear EGFR ( $P = 0.01$ ). Regression analysis was done in these analyses. *B*, lack of correlation between levels of nuclear EGFR and *TWIST* ( $P = 0.6$ ). Regression analysis was similarly done as in *A*. *C*, expression of p-STAT3 correlates with those of *TWIST* and non-nuclear EGFR. Regression analysis was done to determine  $R$  and  $P$  values. *D*, representative tumors immunostained for EGFR, p-STAT3, and *TWIST*. Top, tumor was stained strongly for EGFR (left), p-STAT3 (middle), and *TWIST* (right). Bottom, tumor with negative/low expression for all three proteins.

largely unknown. Moreover, regulation of the mouse *Twist* genes have been investigated to involve tumor necrosis factor- $\alpha$ /nuclear factor  $\kappa$ B (NF- $\kappa$ B; ref. 50) and Wnt1/TCF/ $\beta$ -catenin pathways (51). However, the NF- $\kappa$ B and TCF/ $\beta$ -catenin response elements found in the mouse *Twist* gene promoters are not present in that of the human *TWIST* gene. A recent study reported that STAT3 knockdown of mouse 4T1 mammary tumor cells led to altered expression of several genes, including *Twist* (20). *Twist* has yet been shown to be a direct transcriptional target of STAT3. We did an extensive search, using TF Search and TESS transcription factor search sites, for the STAT-binding sites within the mouse *twist* gene promoter and did not find a putative site, suggesting its expression reduction by STAT3 small interfering RNA was likely due to indirect effects. The current study showed that EGF activated STAT3 sites in the human *TWIST* promoter and regulates its transcription. Because mouse *TWIST* promoter does not contain STAT consensus site, this raises an interesting question that the two species may use STAT to regulate *TWIST* expression through different molecular mechanisms.

The current report strongly supports the notion that EGFR and STAT3 oncoproteins interplay and regulate expression of a series of genes that are involved in aggressive cancer biology. Such regulation, however, seems to be highly complex and not yet fully understood. In the case of *TWIST*, this study indicates that STAT3 plays a direct transcriptional role by binding to the *TWIST* promoter and that EGFR seems to be an upstream regulator that phosphorylates and activates STAT3. Although the responsiveness of EGF of EGFR-NLS/CHO seems to favor that nuclear localization of EGFR might be involved in the STAT3-mediated *TWIST* up-regulation. This notion is not supported by the fact that EGFR-NLS can constitutively activate the *TWIST* promoter. Furthermore, nuclear EGFR does not seem to interact directly with the *TWIST* promoter, as indicated by the ChIP and oligo pull-down assays. IHC studies showed no significant correlation between nuclear EGFR and *TWIST*. Together, these evidences suggest that a role of direct nuclear EGFR in the *TWIST* up-regulation is unlikely. For *iNOS*, nuclear EGFR and STAT3 behave as transcriptional coregulators as the EGFR/STAT3 complex associated with the *iNOS* promoter (24). In the case of cyclin D1, nuclear EGFR seems to bind to the promoter independent of STAT3 (24). On the other hand, STAT3

can be activated by other upstream regulators, independent of EGF/EGFR, and regulates expression of Myc (52) and p21WAF1/CIP1 (53). Further investigations are indeed needed to further our understanding of EGFR-mediated and STAT-mediated gene regulation and its effect in the biology of cancer cells.

We report here that the human *TWIST* gene is directly up-regulated by the oncoprotein STAT3 in cancer cells with high levels of EGFR. This correlation was also found in primary breast carcinomas. Given *TWIST*'s function in promoting EMT, EGFR cooperates with STAT3 to induce *TWIST* expression leading to EMT. In this context, we observed that chronic EGF/TGF- $\alpha$  exposure promotes EMT in breast and pancreatic cancer cells with high EGFR levels. This finding is supported by the observation that prolonged EGF stimulation leads to loss of E-cadherin and increased invasion in A431 human epidermoid carcinoma cells (10). Consistent with our findings, tumors with high EGFR and constitutively activated STAT3 contain high potentials to undergo metastasis (1–5). Stat3 controls cell movement in Zebrafish gastrulation via increasing Zinc transporter LIV1 expression (54, 55). In line with our observations, STAT3 knockdown in mouse breast cancer cell line leads to reduced expression of *Twist* (20). Together, our results and those from other studies highlight an important role of EGFR and STAT3 in promoting cancer EMT via *TWIST*. Our findings provide important insights into the understanding of the malignant biology of tumors with deregulated EGFR and STAT3 pathways and establish new rationales for using anti-EGFR and anti-STAT3 strategies to target aggressive invasive tumors.

## Acknowledgments

Received 2/12/2007; revised 6/12/2007; accepted 7/25/2007.

**Grant support:** NIH grants RO1 109311, P20 CA101936 (MDACC Pancreatic Cancer Specialized Programs of Research Excellence), P50 CA83639 (MDACC Ovarian Cancer Specialized Programs of Research Excellence), and P50 CA116199 (MDACC Breast Cancer Specialized Programs of Research Excellence), Department of Defense Center of Excellence W81XWH-06-2-0033, National Breast Cancer Foundation, Inc. (M.-C. Hung), Cancer Center support grant CA16672, NIH grant 1K01-CA118423-01 (H.-W. Lo), American Cancer Society grant PF TBE-109873, Wendy Will Case Cancer Fund, Elsa U. Pardee Foundation grant (H.-W. Lo), Department of Defense grant W81XWH-07-0390 (H.-W. Lo), and NIH Duke Comprehensive Cancer Center Core grant 5P30 CA14236.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

## References

- Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijken G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. *FEBS Lett* 1998;425:145–50.
- Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. *Cancer Res* 2000;60:2926–35.
- Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. *Mol Cancer Ther* 2003;2:557–61.
- Weber KL, Doucet M, Price JE, et al. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. *Cancer Res* 2003;63:2940–7.
- Shintani S, Li C, Mihara M, Nakashiro K, Hamakawa H. Gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. *Cancer Lett* 2003;201:149–55.
- Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. *Mol Cancer Res* 2003;1:801–9.
- Thomas SM, Coppelli FM, Wells A, et al. Epidermal growth factor receptor-stimulated activation of phospholipase C- $\gamma$ -1 promotes invasion of head and neck squamous cell carcinoma. *Cancer Res* 2003;63:5629–35.
- Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. *Cancer Res* 2001;61:1855–61.
- Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. *Int J Cancer* 1997;70:722–6.
- Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of  $\beta$ -catenin, and enhanced tumor cell invasion. *Cancer Cell* 2003;4:499–515.
- Yang J, Mani SA, Donaher JL, et al. *Twist*, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* 2004;117:927–39.
- Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. *Curr Biol* 2004;14:R719–21.
- Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. *Cancer Res* 2002;62:1613–8.
- Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* 2000;2:76–83.
- Chen ZF, Behringer RR. *twist* is required in head mesenchyme for cranial neural tube morphogenesis. *Genes Dev* 1995;9:686–99.
- Kwok WK, Ling MT, Lee TW, et al. Up-regulation of *TWIST* in prostate cancer and its implication as a therapeutic target. *Cancer Res* 2005;65:5153–62.
- Kyo S, Sakaguchi J, Ohno S, et al. High *Twist* expression is involved in infiltrative endometrial

cancer and affects patient survival. *Hum Pathol* 2006; 37:431–8.

18. Yuen HF, Chan YP, Wong ML, et al. Up-regulation of TWIST in Oesophageal Squamous Cell Carcinoma is associated with neoplastic transformation and distant metastasis. *J Clin Pathol* 2007;60:510–4.

19. Elias MC, Tozer KR, Silber JR, et al. TWIST is expressed in human gliomas and promotes invasion. *Neoplasia* 2005;7:824–37.

20. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. *Cancer Res* 2005;65:2532–6.

21. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene* 2002;21:2000–8.

22. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. *Oncogene* 2003;22:319–29.

23. Yu H, Jove R. The STATs of cancer—new molecular targets come of age. *Nat Rev Cancer* 2004;4:97–105.

24. Lo H-W, Hsu S-C, Ali-Seyed M, et al. Nuclear Interaction of EGFR and STAT3 in the Activation of iNOS/NO Pathway. *Cancer Cell* 2005;7:575–89.

25. Zou Y, Peng H, Zhou B, et al. Systemic Tumor Suppression by the Proapoptotic Gene bik. *Cancer Res* 2002;62:8–12.

26. Lo H-W, Xia W, Wei Y, et al. Novel Prognostic Value of Nuclear EGF Receptor in Breast Cancer. *Cancer Res* 2005;65:338–48.

27. Lee CM, Lo HW, Shao RP, et al. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. *Cancer Res* 2004;64:1788–93.

28. Hanada N, Lo HW, Day CP, et al. Co-regulation of B-Myb expression by E2F1 and EGF receptor. *Mol Carcinog* 2006;45:10–7.

29. Hata A, Seoane J, Lagna G, et al. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. *Cell* 2000;100:229–40.

30. Wegenka UM, Buschmann J, Luttkien C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. *Mol Cell Biol* 1993;13:276–88.

31. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. *J Biol Chem* 1996;271:9503–9.

32. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. *Nat Cell Biol* 2001;3:802–8.

33. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. *Cancer* 1999;86:2259–65.

34. Tai P, Yu E, Vinh-Hung V, Cserni G, Vlastos G. Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries. *BMC Cancer* 2004;4:60.

35. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. *J Biol Chem* 1984;259:7755–60.

36. Wiley HS. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. *J Cell Biol* 1988;107:801–10.

37. Kiyokawa N, Lee EK, Karunagaran D, Lin S-Y, Hung M-C. Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor. *J Biol Chem* 1997;272:18656–65.

38. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ. Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases. *Br J Cancer* 2000;82:1233–8.

39. Darnell JE, Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 1994;264:1415–21.

40. Fu XY. From PTK-STAT signaling to caspase expression and apoptosis induction. *Cell Death Differ* 1999;6:1201–8.

41. Park OK, Schaefer TS, Nathans D. *In vitro* activation of Stat3 by epidermal growth factor receptor kinase. *Proc Natl Acad Sci U S A* 1996;93:13704–8.

42. Bromberg JE, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. *Cell* 1999;98:295–303.

43. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. *Oncogene* 2001;20:2499–513.

44. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. *Cancer Res* 2005;65:9455–62.

45. Lee TK, Poon RTP, Yuen AP, et al. Twist Overexpression Correlates with Hepatocellular Carcinoma Metastasis through Induction of Epithelial-Mesenchymal Transition. *Clin Cancer Res* 2006;12:5369–76.

46. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. *Cancer Res* 2004;64:5270–82.

47. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines *in vitro* sensitivity and predicts clinical activity of erlotinib in lung cancer patients. *Clin Cancer Res* 2005;11:8686–98.

48. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. *Oncogene* 2004;23:474–82.

49. Diaz N, Minton S, Cox C, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. *Clin Cancer Res* 2006;12:20–8.

50. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN. Twist regulates cytokine gene expression through a negative feedback loop that represses NF- $\kappa$ B activity. *Cell* 2003;112:169–80.

51. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. *Cancer Res* 2003; 63:1906–13.

52. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. *Proc Natl Acad Sci U S A* 2001;98:7319–24.

53. Sinibaldi D, Wharton W, Turkson J, et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. *Oncogene* 2000;19:5419–27.

54. Yamashita S, Miyagi C, Carmany-Rampey A, et al. Stat3 Controls Cell Movements during Zebrafish Gastrulation. *Dev Cell* 2002;2:363–75.

55. Yamashita S, Miyagi C, Fukada T, et al. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. *Nature* 2004;429:298–302.

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel on page 1 of the Detailed Cost Estimate form for the initial budget period.

NAME	POSITION TITLE		
Hui-Wen Lo	Assistant Professor		
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Chung-Shan Medical & Dental College, Taiwan The University of Texas at Austin The University of Texas-Health Science Center at Houston, Texas The University of Texas-Health Science Center at Houston, Texas The University of Texas-M.D. Anderson Cancer Center, Texas	B.S. M.A. M.S. Ph.D. POSTDOC	1982 - 1986 1987 - 1990 1992 - 1994 2000 - 2002 2002 - 2004	Nutrition Nutritional Sciences Biomedical Sciences Biochemistry and Molecular Biology Cancer Research

**RESEARCH AND PROFESSIONAL EXPERIENCES****Positions and Employment**

1987	Research Assistant, The University of Texas at Austin
1988-1991	Teaching Assistant, The University of Texas at Austin
1991-1992	Assistant Instructor, The University of Texas at Austin
1993-1998	Senior Research Assistant, Dept. of Experimental Pediatrics, University of Texas M.D. Anderson Cancer Center
1998-2000	Research Investigator, Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center
2002-2004	Postdoctoral Fellow, Department of Molecular and Cellular Oncology, University of Texas M.D. Anderson Cancer Center
2005-2006	Instructor, Department of Molecular and Cellular Oncology, University of Texas M.D. Anderson Cancer Center
2006-present	Assistant Professor (tenure-track), Department of Surgery, Duke University School of Medicine

**Honors and Awards**

1983-1985	Excellence in Academic Performance Awards, Chung-Shan Medical & Dental College, Taiwan
1984-1985	Chia-Shin Academic Scholarships, Chung-Shan Medical & Dental College, Taiwan
1990-1991	Estelle B. Sharp Scholarship, The University of Texas at Austin
2001	John P. McGovern Award, Graduate School of Biomedical Sciences, The University of Texas-Health Science Center
2002	WICR Brigid G. Leventhal Scholar Award, American Association for Cancer Research-Women in Cancer Research
2004&2005	Outstanding Employee Award, Department of Molecular and Cellular Oncology, M.D. Anderson Cancer Center
2004	Outstanding Performance and Excellence in Oral Scientific Presentation Award, Society of Chinese Bioscientists in America-Texas Chapter

2004	AFLAC Scholar-in-Training Award, American Association for Cancer Research
2004	Trainee Excellence Award, Anderson Faculty and Alumni Association, M.D. Anderson Cancer Center
2006	Howard Temin Award, National Cancer Institute
2006	Idea Award, Department of Defense
2008	Career Development Award, Duke Brain Cancer SPORE, NCI

**Publications (over the past 3 years)**

1. **Lo, H.-W.**, Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F. and Hung, M.-C. Novel Prognostic Value of Nuclear EGF Receptor in Breast Cancer. *Cancer Research* 65:338-348, 2005.
2. **Lo, H.-W.**, Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y. and Hung, M.-C. Nuclear Interaction of EGFR and STAT3 in the Activation of iNOS/NO Pathway. *Cancer Cell* 6:575-589, 2005.
3. **Lo, H.-W.**, Day, C.-P., Hung, M.-C. Cancer-specific Gene Therapy. *Advances in Genetics* 54:235-255, 2005.
4. Hanada\*, N., **Lo\***, **H.-W.**, Day, C.-P., Pan, Y., Nakajima, Y. and Hung, M.-C. Co-regulation of B-Myb Expression by E2F1 and EGF Receptor. *Molecular Carcinogenesis* 45:10-17, 2006. (\*These authors contributed equally.)
5. **Lo, H.-W.**, Hsu, S.-C., and Hung, M.-C. EGFR Signaling Pathway in Breast Cancers: from traditional signal transduction to direct nuclear translocalization. *Breast Cancer Research and Treatment* 95:211-218, 2006.
6. **Lo, H.-W.** and Hung, M.-C. Nuclear EGFR Signaling Network in Cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. *British Journal of Cancer* 94:184-188, 2006.
7. **Lo, H.-W.**, Ali-Seyed M., Wu, Y., Bartholomeusz, G., Hsu, Sheng-Chieh, and Hung, M.-C. Nuclear-cytoplasmic Transport of EGFR Involves Receptor Endocytosis, Importin  $\beta$ 1 and CRM1. *Journal of Cellular Biochemistry* 98:1570-1583, 2006.
8. **Lo, H.-W.**, and Ali-Osman, F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. *Current Opinion In Pharmacology* 7:367-74, 2007.
9. **Lo, H.-W.**, Hsu, S-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N. and Hung, M.-C. Epidermal Growth Factor Receptor Cooperates with Signal transducer and activator of transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. *Cancer Research* 67:9066-76, 2007. (Highlighted in "A new twist in metastasis" *Cell* 131:427-427, 2007)
10. **Lo, H.-W.**, Stephenson, L., Cao, X., Milas, M., Pollock, R. and Ali-Osman, F. Identification and functional characterization of the human GSTP1 gene as a novel transcriptional target of the p53 tumor suppressor gene. (*Selected as Journal Highlight*) *Molecular Cancer Research*, 6:843-50, 2008.
11. **Lo\*, H.-W.**, Cao, X., Zhu, H. and Ali-Osman, F. Constitutively activated STAT3 frequently co-expresses with EGFR in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. *Clinical Cancer Research* 2008 (In Press; \*Corresponding Author)

**Earlier Publications**

1. **Lo, H.-W.** and Ali-Osman, F. Genomic cloning of hGSTP1\*C, an allelic human pi class glutathione S-transferase gene variant and functional characterization of its retinoic acid response elements. *Journal of Biological Chemistry* 272:32743-32749, 1997.
2. **Lo, H.-W.** and Ali-Osman, F. Structure of the human allelic glutathione S-transferase- $\pi$  gene variant, hGSTP1\*C, cloned from a glioblastoma multiforme cell line. In: Glutathione and Glutathione Linked Enzymes in Cancer and Other Diseases. Ed: Ali-Osman, F. Elsevier Science, Philadelphia. pp 91-102, 1998.

3. **Lo, H.-W.** and Ali-Osman, F. Differential transactivation of the hGSTP1 promoter by individual direct/everted repeat retinoic acid response elements in intron 5 of the hGSTP1 gene. *Clin. Chem. & Enzym. Commun.* 8, 293-302.2, 2000.
4. **Lo, H.-W.** and Ali-Osman, F. The human glutathione S-transferase P1 (GSTP1) gene is transactivated by cyclic AMP (cAMP) via a cAMP response element (CRE) proximal to the transcription start site. *Chem-Biol. Interactions* 133, 320-321, 2001.
5. **Lo, H.-W.** and Ali-Osman, F. Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: a novel mechanism of cellular GSTP1 gene regulation. *Journal of Cellular Biochemistry* 87:103-116, 2003.
6. Lee, CM.\*, **Lo, H.-W.\***, Shao, R-P., Wang S.-C., Xia, W., Gershenson, DM., Hung, M.-C. Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors: Potential Use for Gene Therapy. (\*These authors contributed equally to this work. Selected for Cancer Research Highlights.) *Cancer Research* 64, 1788-1793, 2004.
7. Wang, S-C., Lien, H-C., Xia, W., Chen, I-F., **Lo, H.-W.**, Wang, Z., Ali-Seyed, M., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and Hung, M.-C. Binding at and transactivation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. *Cancer Cell* 6:251-261, 2004.
8. **Lo, H.-W.**, Antoun, G. and Ali-Osman, F. The Human Glutathione S-Transferase P1 Protein Is Phosphorylated and Its Metabolic Function Enhanced by the Ser/Thr Protein Kinases, cAMP-Dependent Protein Kinase and Protein Kinase C, in Glioblastoma Cells. *Cancer Research* 64, 9131-9138, 2004.

### **Professional Memberships**

1995-present Associate Member, American Association for Cancer Research  
 2000-present Associate Member, Women in Cancer Research  
 2006-present Member, Society of Neuro-oncology  
 2007-present Associate Member, Duke Comprehensive Cancer Center

### **ACTIVE SUPPORT:**

**The Howard Temin Award (5K01-CA118423-02)** Lo (PI) 9/25/06-7/31/11  
 National Cancer Institute  
*“Nuclear EGFR Signaling Network in Human Cancers”*  
 This proposal will (1) characterize the transcriptional co-regulation of the iNOS gene by nuclear interaction of EGFR and STAT3 and determine its role in tumor survival, (2) characterize interaction of EGFR with c-jun and determine its effect on TWIST gene activation and TWIST-mediated breast cancer progression, and (3) determine the role of nuclear EGFR and underlying mechanisms in chemo-resistance.  
*Overlap: NONE*

**Idea Award (W81XWH-07-1-0390)** Lo (PI) 6/1/07-6/30/10  
 Breast Cancer Research Program  
 Department of Defense  
*“Targeting signal transducer and activator of transcription 3 (STAT3) as a novel strategy in sensitizing breast cancer to anti-EGFR therapy”*  
 AIM 1: To determine whether increased STAT3 expression/activity confers resistance to anti-EGFR therapy in EGFR-expressing breast cancer cells. AIM 2: To investigate whether suppression of STAT3 expression/activity sensitizes EGFR-expressing breast cancer cells to anti-EGFR therapy. AIM 3: To determine the therapeutic effects of combined use of anti-EGFR and anti-STAT3 treatments in a mammary tumor-bearing animal model.  
*Overlap: NONE*

Principal Investigator/Program Director (Last, first, middle): LO, HUI-WEN.

**Pediatric Brain Tumor Foundation**

Lo (PI)

4/1/2008-3/31/2014

Targeting Signal Transducer and Activator of Transcription-3 (STAT3) as a Novel Therapy for Pediatric Medulloblastomas

The goal of this study is to determine whether aberrant STAT3 pathway contributes to medulloblastoma biology and if targeting STAT3 leads to significant therapeutic effects.

**Career Development Award**

Lo (PI)

1/1/2008-12/31/2008

Duke Brain Cancer SPORE

National Cancer Institute, Bigner (PI)

STAT3 constitutive activation in resistance of malignant gliomas to anti-EGFR therapy

The goal of this study is to understand the role of STAT3 activation in the resistance of malignant gliomas to anti-EGFR therapy.

**COMPLETED SUPPORT:**

**Elsa U. Pardee Foundation Grant**

Lo (PI)

10/1/06-9/30/07

Role of STAT3 in Resistance to Anti-EGFR Therapy in Human Breast Cancer

**Wendy Will Case Cancer Fund**

Lo (PI)

1/1/06-12/31/06

Nuclear EGFR Signaling Network in Human Cancers

**Postdoctoral Research Fellowship**

Lo (PI)

7/1/05-6/30/07

PF TBE-109873, American Cancer Society

Role of Nuclear EGF Receptor in Human Cancers

On 4/15/2006, the support was terminated due to PI's new position as an independent faculty member (Assistant Professor).

**PENDING SUPPORT:**

**Synergistic Idea Award**

Lo (PI)

4/1/2009-3/31/2011

Breast Cancer Research Program

Department of Defense

RNA Aptamers as a Novel Targeted Therapy for Breast Cancer with Aberrant EGFR and STAT3 Pathways

**RO1**

Zalutsky (PI)

12/1/08-11/30/13

NIH

Modular recombinant transporters: A new platform for 211 At-radiolabeled molecules

The long-term objective of the proposed research is to develop most specific and effective radiopharmaceuticals for cancer treatment that are based on the modular recombinant transporter (MRT) concept.

Role: Co-Investigator

Principal Investigator/Program Director (Last, first, middle): LO, HUI-WEN.

**NIH Director's New Innovator Award**

Lo (PI)

9/30/09-8/31/13

NIH

Novel Comprehensive Screen for Tumor Intravasation Genes and their Regulatory Pathways

The goal of this application is to elucidate the epigenetic mechanisms important for breast cancer intravasation

**Research Scholar Award**

Lo (PI)

1/1/09-12/31/12

American Cancer Society

De-regulated EGFR and STAT3 pathways in breast cancer EMT and intravasation

The goal of this study is to better understand role of EGFR/STAT3 pathway de-regulation in breast cancer EMT and intravasation.